Lance Kates
Arcus Biosciences (United States) · 13 works · 1,200 citations · h-index 10
Top works
- Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes
- Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1
- Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass
- Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
- FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes
- Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor
- Heterogeneity of Satellite Cells Implicates DELTA1/NOTCH2 Signaling in Self-Renewal
- Fully-automated, high-throughput micro-computed tomography analysis of body composition enables therapeutic efficacy monitoring in preclinical models
- Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor Formation
- Adaptive adipose tissue stromal plasticity in response to cold stress and antibody-based metabolic therapy
- GCGR Loss-of-Function Mutations Promote Amino Acid-Dependent Pancreatic Neuroendocrine Tumor Initiation from a Subpopulation of Alpha Cells
- 787 AB598, a CD39 inhibitory antibody, promotes immune-mediated tumor control
- 689 ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action